Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. The EMPA-KIDNEY trial randomised 6609 patients with CKD (estimated glomerular filtration rate [...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 2024-09
Hauptverfasser: Mayne, Kaitlin J, Sardell, Rebecca J, Staplin, Natalie, Judge, Parminder K, Zhu, Doreen, Sammons, Emily, Cherney, David Z I, Green, Jennifer B, Levin, Adeera, Pontremoli, Roberto, Hauske, Sibylle J, Emberson, Jonathan, Preiss, David, Landray, Martin J, Baigent, Colin, Wanner, Christoph, Haynes, Richard, Herrington, William G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. The EMPA-KIDNEY trial randomised 6609 patients with CKD (estimated glomerular filtration rate [eGFR] ≥20 and
ISSN:0931-0509
1460-2385
1460-2385
DOI:10.1093/ndt/gfae203